Treatment of Psoriasis with Mesenchymal Stem Cells
The American Journal of Medicine
Hu Chen, MD, PhDa,b Jing-Wen Niu, MDa,b Hong-Mei Ning, MD, PhDa Xin Pan, MDaXiao-Bin Li, Ph DcYu Li, MDd Dan-Hong Wang, MDa Liang-Ding Hu, MDa Hong-Xia Sheng, MSb Man Xu, MSb Li Zhang, MD, PhDd Bin Zhang, MD, PhDa,b
Psoriasis is an incurable immune-mediated disease, which affects approximately 2% of the world’s population. Current treatments, including newly emerged biologic agents, have some limitations.1 Here, we report 2 cases of psoriasis vulgaris treated by umbilical cord-derived mesenchymal stem cells (UC-MSCs). In these 2 cases, both of the patients remained relapse free for 4 or 5 years.
MSCs are heterogeneous cells that can differentiate into various types of cells and secrete cytokines.2 We gave the fi rst patient MSCs based on 2 reasons: one is that MSCs could support hematopoiesis,3 the other is that MSCs have already been used in autoimmune diseases. 4 Although auto-HSCT may have played a part in the release of the fi rst patient’ s psoriasis, it is still under the risk of relapse.5 The patient who underwent auto- HSCT and UC-MSCs infusion showed no symptoms of psoriatic relapse after nearly 5 years. In addition, MSCs have a unique advantage in terms of safety. We assume that MSCs may be involved in the following 4 aspects: migration to skin lesions, immunomodulation, limitation of autoimmunity, and local paracrine effects. However, more cases are needed to determine the effi cacy of MSCs and their infusion dose, method, and delivery time.